| Citation: | Yanan Guo, Qing Liu, Wei Zhang, Bosen You, Bingmei Liu. A three-gene vasculogenic mimicry-related signature for prognostic stratification of patients with skin cutaneous melanoma[J]. Frigid Zone Medicine, 2026, 6(3): 179-192. doi: 10.1515/fzm-2026-0018 |
| [1] |
Chopra A, Rao U N M. Pathology of melanoma. Surg Clin North Am, 2020; 100(1): 43-59. doi: 10.1016/j.suc.2019.09.004
|
| [2] |
Wang P, Hu L, Fu G, et al. LncRNA MALAT1 Promotes the proliferation, migration, and invasion of melanoma cells by downregulating miR-23a. Cancer Manag Res, 2020; 12: 6553-6562. doi: 10.2147/CMAR.S249348
|
| [3] |
Siegel R L, Kratzer T B, Wagle N S, et al. Cancer statistics, 2021. CA Cancer J Clin, 2021; 71(1): 7-33.
|
| [4] |
Rastrelli M, Tropea S, Rossi C R, et al. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In vivo, 2014; 28(6): 1005-1011.
|
| [5] |
Tanaka R, Kashiwagi S, Ishihara S, et al. A case of malignant melanoma metastasis to the mammary gland. Gan To Kagaku Ryoho, 2014; 41(12): 1939-1941.
|
| [6] |
Braeuer R R, Watson I R, Wu C J, et al. Why is melanoma so metastatic? Pigment Cell Melanoma Res, 2014; 27(1): 19-36. doi: 10.1111/pcmr.12172
|
| [7] |
Bates J E, Youn P, Usuki K Y, et al. Brain metastasis from melanoma: the prognostic value of varying sites of extracranial disease. J Neurooncol, 2015; 125(2): 411-418. doi: 10.1007/s11060-015-1932-9
|
| [8] |
Alqahtani S, Alhefdhi A Y, Almalik O, et al. Primary oral malignant melanoma metastasis to the brain and breast: a case report and literature review. Oncol Lett, 2017; 14(2): 1275-1280. doi: 10.3892/ol.2017.6304
|
| [9] |
Xie R, Dong S, Jiang J, et al. Development and validation of an immune-related gene pair signature in skin cutaneous melanoma. Clin Cosmet Investig Dermatol, 2020; 13: 973-986. doi: 10.2147/CCID.S281364
|
| [10] |
Tracey E H, Vij A. Updates in melanoma. Dermatol Clin, 2019; 37(1): 73-82. doi: 10.1016/j.det.2018.08.003
|
| [11] |
Berk-Krauss J, Stein J A, Weber J, et al. New systematic therapies and trends in cutaneous melanoma deaths among US whites, 1986-2016. Am J Public Health, 2020; 110(5): 731-733. doi: 10.2105/AJPH.2020.305567
|
| [12] |
Bommareddy P K, Silk A W, Kaufman H L. Intratumoral approaches for the treatment of melanoma. Cancer J, 2017; 23(1): 40-47. doi: 10.1097/PPO.0000000000000234
|
| [13] |
Gide T N, Mao Y, Scolyer R A, et al. Tissue-based profiling techniques to achieve precision medicine in cancer: opportunities and challenges in melanoma. Clin Cancer Res, 2024; 30(23): 5270-5280. doi: 10.1158/1078-0432.CCR-24-1109
|
| [14] |
Luo Q, Wang J, Zhao W, et al. Vasculogenic mimicry in carcinogenesis and clinical applications. J Hematol Oncol, 2020; 13(1): 19. doi: 10.1186/s13045-020-00858-6
|
| [15] |
Maniotis A J, Folberg R, Hess A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro vasculogenic mimicry. Am J Pathol, 1999; 155(3): 739-752. doi: 10.1016/S0002-9440(10)65173-5
|
| [16] |
Serratì S, Roca M, D'Atri S, et al. Unraveling vascular mechanisms in melanoma: roles of angiogenesis and vasculogenic mimicry in tumor progression and therapeutic resistance. Cancer Biol Med, 2025; 22(11): 1327-1352. doi: 10.20892/j.issn.2095-3941.2025.0048
|
| [17] |
Yang J P, Liao Y D, Mai D M, et al. Tumor vasculogenic mimicry predicts poor prognosis in cancer patients: a meta-analysis. Angiogenesis, 2016; 19(2): 191-200. doi: 10.1007/s10456-016-9500-2
|
| [18] |
Liu R, Yang K, Meng C, et al. Vasculogenic mimicry is a marker of poor prognosis in prostate cancer. Cancer Biol Ther, 2012; 13(7): 527-533. doi: 10.4161/cbt.19602
|
| [19] |
Delgado-Bellido D, Serrano-Saenz S, Fernández-Cortés M, et al. Vasculogenic mimicry signaling revisited: focus on non-vascular VE-cadherin. Mol Cancer, 2017; 16(1): 65. doi: 10.1186/s12943-017-0631-x
|
| [20] |
Wang W, Lin P, Sun B, et al. Epithelial-mesenchymal transition regulated by EphA2 contributes to vasculogenic mimicry formation of head and neck squamous cell carcinoma. Biomed Res Int, 2014; 2014: 803914.
|
| [21] |
Comito G, Calvani M, Giannoni E, et al. HIF-1α stabilization by mitochondrial ROS promotes Met-dependent invasive growth and vasculogenic mimicry in melanoma cells. Free Radic Biol Med, 2011; 51(4): 893-904. doi: 10.1016/j.freeradbiomed.2011.05.042
|
| [22] |
Schnegg C I, Yang M H, Ghosh S K, et al. Induction of vasculogenic mimicry overrides VEGF-A silencing and enriches stem-like cancer cells in melanoma. Cancer Res, 2015; 75(8): 1682-1690. doi: 10.1158/0008-5472.CAN-14-1855
|
| [23] |
Mao X G, Xue X Y, Wang L, et al. CDH5 is specifically activated in glioblastoma stem-like cells and contributes to vasculogenic mimicry induced by hypoxia. Neuro Oncol, 2013; 15(7): 865-879. doi: 10.1093/neuonc/not029
|
| [24] |
Ma X L, Zhu K P, Zhang C L. Circular RNA circ_HIPK3 is down-regulated and suppresses cell proliferation, migration and invasion in osteosarcoma. J Cancer, 2018; 9(10): 1856-1862. doi: 10.7150/jca.24619
|
| [25] |
Meng J, Chen S, Lei Y Y, et al. Hsp90β promotes aggressive vasculogenic mimicry via epithelial-mesenchymal transition in hepatocellular carcinoma. Oncogene, 2019; 38(2): 228-243. doi: 10.1038/s41388-018-0428-4
|
| [26] |
Camorani S, Crescenzi E, Gramanzini M, et al. Aptamer-mediated impairment of EGFR-integrin αvβ3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers. Sci Rep, 2017; 7: 46659. doi: 10.1038/srep46659
|
| [27] |
Wu S, Yu L, Wang D, et al. Aberrant expression of CD133 in non-small cell lung cancer and its relationship to vasculogenic mimicry. BMC Cancer, 2012; 12: 535. doi: 10.1186/1471-2407-12-535
|
| [28] |
Li Y, Chen D, Jin L, et al. Long non-coding RNA MALAT1 promotes gastric cancer tumorigenicity and metastasis by regulating vasculogenic mimicry and angiogenesis. Cancer Lett, 2017; 395: 31-44. doi: 10.1016/j.canlet.2017.02.035
|
| [29] |
Li W, Zong S Q, Shi Q, et al. Hypoxia-induced vasculogenic mimicry formation in human colorectal cancer cells: involvement of HIF-1α, Claudin-4, E-cadherin and Vimentin. Sci Rep, 2016; 6: 37534. doi: 10.1038/srep37534
|
| [30] |
Ge H, Luo H. Overview of advances in vasculogenic mimicry: a potential target for tumor therapy. Cancer Manag Res, 2018; 10: 2429-2437. doi: 10.2147/CMAR.S164675
|
| [31] |
Qiao L, Liang N, Zhang J, et al. Advanced research on vasculogenic mimicry in cancer. J Cell Mol Med, 2015; 19(2): 315-326. doi: 10.1111/jcmm.12496
|
| [32] |
Wang Y B, Zou L X, Song M Z, et al. Establishment of skin cutaneous melanoma prognosis model based on vascular mimicry risk score. Medicine (Baltimore), 2024; 103(7): e36679. doi: 10.1097/MD.0000000000036679
|
| [33] |
Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw, 2010; 33(1): 1-22.
|
| [34] |
Tao C, Huang K, Shi J, et al. Genomics and prognosis analysis of epithelial-mesenchymal transition in glioma. Front Oncol, 2020; 10: 183. doi: 10.3389/fonc.2020.00183
|
| [35] |
Zhang W, Liu Z, Wang J, et al. The clinical significance, immune infiltration, and tumor mutational burden of angiogenesis-associated lncRNAs in kidney renal clear cell carcinoma. Front Immunol, 2022; 13: 934387. doi: 10.3389/fimmu.2022.934387
|
| [36] |
Hong C S, Sun E G, Choi J, et al. Fibroblast growth factor receptor 4 increases epidermal growth factor receptor (EGFR) signaling by inducing amphiregulin expression and attenuates response to EGFR inhibitors in colon cancer. Cancer Sci, 2020; 111(9): 3268-3278. doi: 10.1111/cas.14526
|
| [37] |
Lanaya H, Natarajan A, Komposch K, et al. EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation. Nat Cell Biol, 2014; 16(10): 972-977. doi: 10.1038/ncb3031
|
| [38] |
Rose M, Maurer A, Wirtz J, et al. EGFR activity addiction facilitates anti-ERBB-based combination treatment of squamous bladder cancer. Oncogene, 2020; 39(44): 6856-6870. doi: 10.1038/s41388-020-01465-y
|
| [39] |
Seguin L, Kato S, Franovic A, et al. An integrin β3-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat Cell Biol, 2014; 16(5): 457-468. doi: 10.1038/ncb2953
|
| [40] |
Caramel J, Ligier M, Puisieux A. Pleiotropic roles for ZEB1 in cancer. Cancer Res, 2018; 78(1): 30-35. doi: 10.1158/0008-5472.CAN-17-2476
|
| [41] |
Wu H T, Zhong H T, Li G W, et al. Oncogenic functions of the EMT-related transcription factor ZEB1 in breast cancer. J Transl Med, 2020; 18(1): 51. doi: 10.1186/s12967-020-02240-z
|
| [42] |
Sierra J R, Corso S, Caione L, et al. Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages. J Exp Med, 2008; 205(7): 1673-1685. doi: 10.1084/jem.20072602
|
| [43] |
Limonta P, Chiaramonte R, Casati L. Unveiling the dynamic interplay between cancer stem cells and the tumor microenvironment in melanoma: implications for novel therapeutic strategies. Cancers (Basel), 2024; 16(16): 2861. doi: 10.3390/cancers16162861
|
| [44] |
Trocchia M, Ventrici A, Modestino L, et al. Innate immune cells in melanoma: implications for immunotherapy. Int J Mol Sci, 2024; 25(15): 8523. doi: 10.3390/ijms25158523
|
| [45] |
Tas F, Erturk K. Seasons influence diagnosis and outcome of cutaneous melanoma. Dermatol Ther, 2020; 33(4): e13625.
|
fzm-6-3-179_Supplementary figS1.zip
|
|
fzm-6-3-179_Supplementary data Table1.xlsx
|
|
fzm-6-3-179_Supplementary figS2.zip
|
|